1.5.12
Tobira Therapeutics Continues Management Team Expansion
8.8.11
Tobira Therapeutics Announces Key Management Team Additions
7.19.11
Tobira Therapeutics Presents Pharmacokinetics and Safety Data that Support Coadministration of Cenicriviroc with Tenofovir DF in Healthy Adults
Poster Presentation
A Phase I, Open-Label, Single-Dose, Randomized, Cross-Over Study of Cenicriviroc (CVC) and Tenofovir (TDF) in Healthy Volunteers
6.22.11
Tobira Therapeutics Initiates Phase IIb Trial of Cenicriviroc, a Novel CCR5/CCR2 Antagonist for the Treatment of HIV Infection
4.4.11
Tobira Therapeutics Appoints Andrew Hindman President and Chief Executive Officer
2.28.11
Tobira Therapeutics Reports Encouraging Pharmacokinetic, Bioavailability and Safety Results from Studies of Cenicriviroc
Poster Presentation
Cenicriviroc (CVC, TBR-652) Absorption, Distribution, Metabolism and Excretion (ADME) Profile in Rats, Dogs, Monkeys and Humans
9.29.10
Tobira Announces $31 Million Series B Raise; Phase llb Plans
Poster Presentation
Similarity in Pharmacokinetics of TBR-652, A Chemokine Receptor 5 (CCR5) Antagonist, in Healthy and HIV-1 Infected Subjects
Oral Presentation
TBR-652, A Potent Dual Chemokine Receptor 5/Chemokine Receptor 2 (CCR5/CCR2) Antagonist in Phase 2 Development for Treatment of HIV Infection
7.19.10
Tobira's Next-Generation Once-Daily CCR5/CCR2 Antagonist Demonstrates Potent CCR2 Inhibition, Antiviral Activity, Safety and Tolerability In Treatment-Experienced Patients With HIV; TBR-652 Phase IIa Data Presented at XVIII International AIDS Conference Showcase Potentially Important Anti-Inflammatory Benefits
2.17.10
Pharmacokinetic/Pharmacodynamic Data Support Further Development Of Tobira's Next-Generation CCR5 Receptor Antagonist
2.17.10
Tobira's Next-Generation Once-Daily CCR5 Receptor Antagonist Demonstrates Efficacy, Safety and Tolerability In Treatment-Experienced Patients With HIV
Poster Presentation
Pharmacokinetics (PK) and Pharmacodynamics (PD) of TBR-652, A Chemokine Receptor 5 (CCR5) Antagonist, In HIV-1-Infected, Antiretorviral (ARV) Treatment-Experienced, CCR5 Antagonist-Naïve Patients
11.12.09
Tobira Therapeutics Inc. Announce Presentation of TBR-652 Data at European AIDS Conference
Poster Presentation
A Chemokine Receptor 5 (CCR5) Antagonist, Demonstrates Good Oral Bioavailability and Desirable Pharmacokinetic (PK) and Safety Profiles In Healthy Volunteers
Poster Presentation
In Vitro Anti-HIV Efficacy of The Chemokine Receptor 5 (CCR5) Antagonist TBR-652 In Combination With Four Other Classes Of Antiretroviral Agents
7.22.09
Tobira IAS 2009 Poster - Effect of Food on the Relative Bioavailabiliy and Pharmacokinetics of TBR652
Tobira Poster Presentation
Pharmacokinetics, Safety and Tolerabilityof Single Doses of TBR652 in Healthy Volunteers
7.22.09
Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 For The Treatment of HIV
6.4.09
Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
4.8.09
Tobira Therapeutics Inc. Initiates Proof of Concept Study With TAK-652 For The Treatment of HIV
8.18.08
Tobira Therapeutics Inc. Receives US Patent for TBR-652
6.30.08
Tobira Therapeutics Inc. Announces Leadership Team Possessing Over 130 Years of Cumulative Expertise |
